Search

Your search keyword '"Yunokawa, Mayu"' showing total 578 results
Start Over Author "Yunokawa, Mayu"
578 results on '"Yunokawa, Mayu"'

1. The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience

Author

Yunokawa, Mayu, Abe, Akiko, Wang, Xiaofei, Toyohara, Yusuke, Nimura, Ryo, Komoto, Takayuki, Misaka, Satoki, Yoshimitsu, Teruyuki, Ikki, Ai, Kamata, Mayumi, Nishino, Shogo, Kanno, Motoko, Fusegi, Atsushi, Netsu, Sachiho, Aoki, Yoichi, Omi, Makiko, Tanigawa, Terumi, Okamoto, Sanshiro, Nomura, Hidetaka, and Kanao, Hiroyuki

Published
2024
Full Text
View/download PDF

4. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Author

Marth, Christian, Moore, Richard G., Bidziński, Mariusz, Pignata, Sandro, Ayhan, Ali, Rubio, M. Jesús, Beiner, Mario, Hall, Marcia, Vulsteke, Christof, Braicu, Elena Ioana, Sonoda, Kenzo, Wu, Xiaohua, Frentzas, Sophia, Mattar, André, Lheureux, Stephanie, Chen, Xiaojun, Hasegawa, Kosei, Magallanes-Maciel, Manuel, Choi, Chel Hun, Shalkova, Mariia, Kaen, Diego, Wang, Peng-Hui, Berger, Regina, Okpara, Chinyere E., McKenzie, Jodi, Yao, Lili, Orlowski, Robert, Khemka, Vivek, Gilbert, Lucy, Makker, Vicky, Kaen, Diego Lucas, Gomez Abuin, Gonzalo, Zamora, Liliana Beatriz, Alfie, Margarita Sonia, Casarini, Ignacio Alfredo, Harrison, Michelle, Ananda, Sumitra, Shannon, Catherine Margaret, Frentzas, Sophia, Friedlander, Michael, Meniawy, Tarek, Gao, Bo, Baron-Hay, Sally, Diakos, Connie, Marth, Christian, Polterauer, Stephan, Petru, Edgar, De Bock, Marlies, Vulsteke, Christof, Baurain, Jean-Francois, Van Gorp, Toon, Altintas, Sevilay, Lima, Joao Paulo da Silveira Nogueira, Mattar, Andre, de Freitas Junior, Ruffo, Santana, Rosane O., de Melo, Andreia Cristina, Franke, Fabio Andre, Zibetti Dal Molin, Graziela, Damian, Fernanda Bronzon, Guedes, João Daniel Cardoso, Ellard, Susan, Tinker, Anna, Samouëlian, Vanessa, Fortin, Suzanne, Bessette, Paul, Kolinsky, Michael, Kumar Tyagi, Nidhi, Ethier, Josee-Lyne, Gilbert, Lucy, Lheureux, Stephanie, MacKay, Helen, Lim, Charles, Wu, Xiaohua, Pan, Lingya, An, Ruifang, Chen, Xiaojun, Zheng, Hong, Wu, Yumei, Zhu, Jianqing, Yao, Shuzhong, Jia, Xuemei, Huang, Yi, Lv, Weiguo, Zhang, Yu, Zhou, Qi, Ma, Cailing, Chekerov, Radoslav, Mach, Pawel, Witteler, Ralf, Marmè, Frederik, Cadoo, Karen, Korach, Jacob, Levy, Talia, Beiner, Mario, Amnon, Amit, Scollo, Paolo, Naglieri, Emanuele, Pignata, Sandro, Zamagni, Claudio, Salutari, Vanda, Usami, Tomoka, Nakamura, Kazuto, Matsumoto, Koji, Yamagami, Wataru, Kobayashi, Yoichi, Takano, Masashi, Kato, Hidenori, Sonoda, Kenzo, Kikuchi, Akira, Katsumata, Noriyuki, Kamiura, Shoji, Horie, Koji, Hasegawa, Kosei, Tsunoda, Takuya, Suzuki, Nao, Yunokawa, Mayu, Nishio, Shin, Kudaka, Wataru, Guerrero Cabrera, Fernando Felix, Gonzalez Mendoza, Rene Lazaro, Magallanes Maciel, Manuel Ernesto, Villalobos Valencia, Ricardo, Escobar Penagos, Jose, Lopez Chuken, Yamil Alonso, Mackowiak-Matejczyk, Beata, Tarnawski, Rafal, Kalinka, Ewa, Bidzinski, Mariusz, Bednarek, Wieslawa, Danska-Bidzinska, Anna, Koralewski, Piotr, Roszak, Andrzej, Kedrova, Anna, Musaeva, Natalia, Urmancheeva, Adiliya Fettekhovna, Vasiliev, Aleksandr Gennadievich, Safina, Sufia Zievna, Lisyanskaya, Alla Sergeevna, Rykov, Ivan V., Rumyantsev, Alexey Alexandrovich, Belonogov, Aleksandr, Makarycheva, Yulia, Kim, Yong Man, Choi, Chel Hun, Kim, Yong Beom, Kim, Hee Seung, Kim, Sang Wun, Quindos Varela, Maria, Casado Herraez, Antonio, Diaz Redondo, Tamara, Rubio Perez, Maria Jesus, Romeo Marin, Margarita, Romero Noguera, Ignacio, Taus Garcia, Alvaro, Lin, Wu-Chou, Chou, Hung-Hsueh, Cheng, Wen-Fang, Lu, Chien-Hsing, Wang, Peng-Hui, Simsek, Tayup, Kose, Fatih, Ayhan, Ali, Vardar, Mehmet Ali, Ozerkan, Kemal, Hughes, Andrew, Stillie, Alison, Eminowicz, Gemma, Khalique, Saira, Shalkova, Mariia, Sukhina, Olena, Piatnytska, Tetiana, Averina, Hanna, Kulyaba, Yaroslav, Kryzhanivska, Anna, Bondarenko, Igor, Svintsitsky, Valentyn, Krasnohrud, Yuliia, Voitko, Nataliia, Buscema, Joseph, Ghamande, Sharad, Lewin, Sharyn, Graham, Deena M., Makker, Vicky, Bell, Maria, Santin, Alessandro, Lee, Christine, Blank, Stephanie, Konecny, Gottfried E., Corr, Bradley, Van Le, Linda, Moore, Richard G., Scalici, Jennifer, Anderson, Charles, Braly, Patricia, Fehniger, Julia, Westhoff, Gina, and Bollinger, Lauren

Published
2024
Full Text
View/download PDF

6. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

7. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan

Author

Nomura, Hidetaka, Abe, Akiko, Fusegi, Atsushi, Yoshimitsu, Teruyuki, Misaka, Satoki, Murakami, Atsushi, Matsumoto, Tsuyoshi, Tsumura, Shiho, Kanno, Motoko, Aoki, Yoichi, Netsu, Sachiho, Omi, Makiko, Tanigawa, Terumi, Okamoto, Sanshiro, Omatsu, Kohei, Yunokawa, Mayu, Kanao, Hiroyuki, Habano, Eri, Arakawa, Hiromi, Kaneko, Keika, Ueki, Arisa, Haruyama, Yurie, Inari, Hitoshi, and Ueno, Takayuki

Published
2023
Full Text
View/download PDF

9. Influence of COVID‐19 on the clinical characteristics of patients with uterine cervical cancer in Japan: A single‐center retrospective study.

Author

Murakami, Atsushi, Nomura, Hidetaka, Abe, Akiko, Fusegi, Atsushi, Aoki, Yoichi, Omi, Makiko, Tanigawa, Terumi, Okamoto, Sanshiro, Yunokawa, Mayu, and Kanao, Hiroyuki

Subjects
UTERINE tumors, CERVICAL intraepithelial neoplasia, SQUAMOUS cell carcinoma, CANCER treatment, CERVIX uteri tumors, CANCER invasiveness, DATA analysis, NOMADS, EARLY detection of cancer, KRUSKAL-Wallis Test, SYMPTOMS, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, CHI-squared test, TERTIARY care, URBAN hospitals, MEDICAL records, ACQUISITION of data, STATISTICS, CERVICAL cancer, TUMOR classification, COVID-19 pandemic, MEDICAL referrals, SPECIALTY hospitals
Abstract

Aim: This study investigated the impact of coronavirus disease 2019 (COVID‐19) on the clinical characteristics and interregional movement of patients with uterine cervical cancer. Methods: This study included 1189 patients who underwent treatment for cervical cancer, including cervical intraepithelial neoplasm and adenocarcinoma in situ, at our hospital in Tokyo, Japan, in 2017–2018 and in 2021, before and after the pandemic, respectively. The patients' clinical information was compared during both periods. The clinical stage was unified using the International Federation of Gynecology and Obstetrics (FIGO) 2008 staging. Results: The number of patients treated for cervical cancer was 355, 420, and 414 in 2017, 2018, and 2021, respectively. The percentage of invasive carcinomas significantly increased from 158 (44.5%) and 196 (46.7%) to 219 (52.9%) (p = 0.049). In all periods, no significant differences were observed in median age, histological type, and treatment. The proportions of FIGO Stage IA1 were significantly elevated from 3.9% and 3.8% to 11.4% (p < 0.001). The percentage of patients from prefectures other than Tokyo significantly increased from 34.9% to 40.8% (p = 0.049). Furthermore, the proportion of patients with invasive carcinoma in private clinics increased from 28.0% to 37.9% (p = 0.014). Conclusions: The number of patients with invasive carcinoma and the percentage of patients with invasive carcinoma referred from private clinics increased, indicating that the COVID‐19 pandemic influenced patients to delay consultations. Furthermore, the surge in patients from other prefectures indicates that medical resources were more limited in rural areas, another impact of COVID‐19. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer

Author

Kanno, Motoko, Yunokawa, Mayu, Nakabayashi, Makoto, Omi, Makiko, Ikki, Ai, Mizusaki, Megumi, Nishimura, Mai, Shimizu, Yusuke, Okamoto, Kota, Tanaka, Yuji, Fusegi, Atsushi, Netsu, Sachiho, Kurita, Tomoko, Aoki, Yoichi, Tanigawa, Terumi, Matoda, Maki, Okamoto, Sanshiro, Nomura, Hidetaka, Omatsu, Kohei, Sugiyama, Yuko, Utsugi, Kuniko, Takeshima, Nobuhiro, and Kanao, Hiroyuki

Published
2022
Full Text
View/download PDF

14. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, De La Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Hoon Kim, Jae, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez De Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Weon Kim, Jae, Hegg, Roberto, Vergote, Ignace, Poveda, Andrés, Ledermann, Jonathan A, Asher, Rebecca, Penson, Richard T, Oza, Amit M, Baldoni, Alessandra, Sonke, Gabe S, Kim, Jae-Hoon, Filho, Elias Abdo, Milenkova, Tsveta, Lowe, Elizabeth S, Rowe, Phil, and Pujade-Lauraine, Eric

Published
2021
Full Text
View/download PDF

15. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Abstract

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient

Published
2024

17. A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study

Author

Komatsu, Hiroaki, primary, Matsumoto, Koji, additional, Morita, Mitsunori, additional, Nagasawa, Takayuki, additional, Nishio, Hiroshi, additional, Suzuki, Jiro, additional, Nishio, Shin, additional, Kobara, Hisanori, additional, Yunokawa, Mayu, additional, Ariyoshi, Kazuya, additional, Hirayama, Takashi, additional, Tokunaga, Hideki, additional, Ukita, Masayo, additional, Yoriki, Kaori, additional, Mori‐Uchino, Mayuyo, additional, Furusawa, Akiko, additional, Togami, Shinichi, additional, Nakamura, Hiroko, additional, Ishikawa, Mitsuya, additional, and Satoh, Toyomi, additional

Published
2024
Full Text
View/download PDF

20. Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

Author

Yonemori, Kan, primary, Fujiwara, Keiichi, additional, Hasegawa, Kosei, additional, Yunokawa, Mayu, additional, Ushijima, Kimio, additional, Suzuki, Shiro, additional, Shikama, Ayumi, additional, Minobe, Shinichiro, additional, Usami, Tomoka, additional, Kim, Jae-Weon, additional, Kim, Byoung-Gie, additional, Wang, Peng-Hui, additional, Chang, Ting-Chang, additional, Yamamoto, Keiko, additional, Han, Shirong, additional, McKenzie, Jodi, additional, Orlowski, Robert J., additional, Miura, Takuma, additional, Makker, Vicky, additional, and Man Kim, Yong, additional

Published
2024
Full Text
View/download PDF

25. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Author

Aggarwal, Simi, Bronger, Holger, Brown, Elizabeth B., Buck, Martin, Bukhari, Syed A., Coghlan, Edwina, Cope, Nichola, de Almeida, Michelle Samora, De Kroon, Cornelius D., Dean, Andrew, Devlin, Michael-John, Ditzel, Helena M., Drecoll, Enken, Ebata, Takahiro, Fagotti, Anna, Faruqi, Asma, Feeney, Laura, Gupta, Kavita, Harley, Ian, Inzani, Frediano, Jeyarajah, Arjun R., Koay, M.H. Eleanor, Kroep, Judith R., Lee, Jung-Yun, Leung, Yee, Lockley, Michelle, Loft, Alice R., MaGee, Daniel, Manchanda, Ranjit, McKenna, Sarah, Midha, Divya, Millan, David, Millar, Joanne, Miller, Rowan, Mohan, Ganendra R., Mughal, Sohail, Mukhopadhyay, Asima, Nicolau, Sergio Mancini, Nevin, James, Oakley, Abigail S., Quigley, Mary, Rai, Bhavana, Rajwanshi, Arvind, Salfinger, Stuart G., Scambia, Giovanni, Scatchard, Kate, Schmalfeldt, Barbara, Simcock, Bryony, Singh, Priya, Strickland, Kyle C., Suri, Vainta, Syed, Sheeba, Sykes, Peter, Tamura, Kenji, Tan, Adeline, Tan, Jason, Thompson, Emily, Tinker, Anna V., Trevisan, Georgia, Uyeda, Maria Gabriela Baumgarten Kuster, Vaughan, Michelle M., Weichert, Wilko, Williams, Anthony, Williams, Sarah, Yoshida, Hiroshi, Zorzato, Pier Carlo, Cohen, Paul A., Powell, Aime, Böhm, Steffen, Gilks, C. Blake, Stewart, Colin J.R., Meniawy, Tarek M., Bulsara, Max, Avril, Stefanie, Brockbank, Eleanor C., Bosse, Tjalling, de Azevedo Focchi, Gustavo Rubino, Ganesan, Raji, Glasspool, Rosalind M., Howitt, Brooke E., Kim, Hyun-Soo, Le, Nhu D., Mandalia, Trupti, McCluggage, W. Glenn, McNeish, Iain, Srinivasan, Radhika, Tan, Yun Yi, van der Griend, Rachael, Yunokawa, Mayu, Zannoni, Gian F., and Singh, Naveena

Published
2019
Full Text
View/download PDF

26. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years

Author

Matsuo, Koji, Ross, Malcolm S., Yunokawa, Mayu, Johnson, Marian S., Machida, Hiroko, Omatsu, Kohei, Klobocista, Merieme M., Im, Dwight D., Satoh, Shinya, Baba, Tsukasa, Ikeda, Yuji, Bush, Stephen H., Hasegawa, Kosei, Blake, Erin A., Takekuma, Munetaka, Shida, Masako, Nishimura, Masato, Adachi, Sosuke, Pejovic, Tanja, Takeuchi, Satoshi, Yokoyama, Takuhei, Ueda, Yutaka, Iwasaki, Keita, Miyake, Takahito M., Yanai, Shiori, Nagano, Tadayoshi, Takano, Tadao, Shahzad, Mian MK., Ueland, Frederick R., Kelley, Joseph L., and Roman, Lynda D.

Published
2019
Full Text
View/download PDF

27. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

Author

Murakami, Ryusuke, Matsumura, Noriomi, Michimae, Hirofumi, Tanabe, Hiroshi, Yunokawa, Mayu, Iwase, Haruko, Sasagawa, Motoi, Nakamura, Toshiaki, Tokuyama, Osamu, Takano, Masashi, Sugiyama, Toru, Sawasaki, Takashi, Isonishi, Seiji, Takehara, Kazuhiro, Nakai, Hidekatsu, Okamoto, Aikou, Mandai, Masaki, and Konishi, Ikuo

Published
2019
Full Text
View/download PDF

28. Ovarian surveillance including endometrial cytology for patients with hereditary breast and ovarian cancer before risk‐reducing salpingo‐oophorectomy: A retrospective analysis.

Author

Fusegi, Atsushi, Nomura, Hidetaka, Ueki, Arisa, Abe, Akiko, Kamata, Mayumi, Misaka, Satoki, Aoki, Yoichi, Tanigawa, Terumi, Yunokawa, Mayu, and Kanao, Hiroyuki

Subjects
PUBLIC health surveillance, CYTOLOGY, ENDOMETRIUM, SALPINGO-oophorectomy, OVARIAN tumors, BREAST tumors, ENDOSCOPIC ultrasonography, RETROSPECTIVE studies, MEDICAL records, ACQUISITION of data
Abstract

Aim: Ovarian surveillance in women with hereditary breast and ovarian cancer who do not undergo risk‐reducing salpingo‐oophorectomy has been controversial. Therefore, this study aimed to demonstrate the clinical features of ovarian surveillance at our institution using a technique that combines serum cancer antigen 125 measurements, transvaginal ultrasonography, and uterine endometrial cytology. Methods: We retrospectively examined 65 women, who had not undergone risk‐reducing salpingo‐oophorectomy diagnosed with hereditary breast and ovarian cancer between 2000 and 2021 at our hospital. Clinical information was obtained and analyzed through a chart review. The details of the treatment course were reviewed for patients who had developed ovarian cancer. Results: Overall, 5 of the 65 women were diagnosed with ovarian cancer based on abnormal findings during periodic surveillance. All patients who developed ovarian cancer were asymptomatic, even if the cancer was at an advanced stage. Two of the 65 patients had endometrial cytology abnormalities, both of whom had ovarian cancer. All patients who developed ovarian cancer underwent primary debulking surgery, and complete gross resection was achieved. None of the patients experienced ovarian cancer recurrence. Conclusions: The ovarian surveillance strategy at our institution for women with hereditary breast and ovarian cancer who do not undergo risk‐reducing salpingo‐oophorectomy can identify asymptomatic ovarian cancer and contribute to achieving complete gross resection during primary surgery. Ovarian surveillance may contribute to a reduction in ovarian cancer mortality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO

Author

Abe, Akiko, primary, Nomura, Hidetaka, additional, Fusegi, Atsushi, additional, Yunokawa, Mayu, additional, Ueki, Arisa, additional, Habano, Eri, additional, Arakawa, Hiromi, additional, Kaneko, Keika, additional, Minoura, Yuko, additional, Inari, Hitoshi, additional, Ueno, Takayuki, additional, and Kanao, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

31. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, and Yunokawa, Mayu

Abstract

The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Published
2024
Full Text
View/download PDF

32. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M.K., Im, Dwight D., Yoshida, Hiroshi, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

33. Significance of venous thromboembolism in women with uterine carcinosarcoma

Author

Matsuo, Koji, Ross, Malcolm S., Im, Dwight D., Klobocista, Merieme M., Bush, Stephen H., Johnson, Marian S., Takano, Tadao, Blake, Erin A., Ikeda, Yuji, Nishimura, Masato, Ueda, Yutaka, Shida, Masako, Hasegawa, Kosei, Baba, Tsukasa, Adachi, Sosuke, Yokoyama, Takuhei, Satoh, Shinya, Machida, Hiroko, Yanai, Shiori, Iwasaki, Keita, Miyake, Takahito M., Takeuchi, Satoshi, Takekuma, Munetaka, Nagano, Tadayoshi, Yunokawa, Mayu, Pejovic, Tanja, Omatsu, Kohei, Shahzad, Mian M.K., Kelley, Joseph L., Ueland, Frederick R., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

38. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Author

Matsuo, Koji, Ross, Malcolm S., Yunokawa, Mayu, Johnson, Marian S., Machida, Hiroko, Omatsu, Kohei, Klobocista, Merieme M., Im, Dwight D., Satoh, Shinya, Baba, Tsukasa, Ikeda, Yuji, Bush, Stephen H., Hasegawa, Kosei, Blake, Erin A., Takekuma, Munetaka, Shida, Masako, Nishimura, Masato, Adachi, Sosuke, Pejovic, Tanja, Takeuchi, Satoshi, Yokoyama, Takuhei, Ueda, Yutaka, Iwasaki, Keita, Miyake, Takahito M., Yanai, Shiori, Nagano, Tadayoshi, Takano, Tadao, Shahzad, Mian M.K., Ueland, Frederick R., Kelley, Joseph L., and Roman, Lynda D.

Published
2017
Full Text
View/download PDF

39. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, de la Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Kim, Jae Hoon, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez de Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Kim, Jae Weon, Hegg, Roberto, Vergote, Ignace, Pujade-Lauraine, Eric, Ledermann, Jonathan A, Gebski, Val, Penson, Richard T, Oza, Amit M, Poveda, Andrés, Fujiwara, Keiichi, Liu, Joyce, Lowe, Elizabeth S, and Bloomfield, Ralph

Published
2017
Full Text
View/download PDF

40. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma

Author

Matsuo, Koji, Omatsu, Kohei, Ross, Malcolm S., Johnson, Marian S., Yunokawa, Mayu, Klobocista, Merieme M., Im, Dwight D., Bush, Stephen H., Ueda, Yutaka, Takano, Tadao, Blake, Erin A., Hasegawa, Kosei, Baba, Tsukasa, Shida, Masako, Satoh, Shinya, Yokoyama, Takuhei, Machida, Hiroko, Adachi, Sosuke, Ikeda, Yuji, Iwasaki, Keita, Miyake, Takahito M., Yanai, Shiori, Nishimura, Masato, Nagano, Tadayoshi, Takekuma, Munetaka, Takeuchi, Satoshi, Pejovic, Tanja, Shahzad, Mian MK, Ueland, Frederick R., Kelley, Joseph L., and Roman, Lynda D.

Published
2017
Full Text
View/download PDF

41. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma

Author

Matsuo, Koji, Ross, Malcolm S., Bush, Stephen H., Yunokawa, Mayu, Blake, Erin A., Takano, Tadao, Ueda, Yutaka, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Yanai, Shiori, Klobocista, Merieme M., Johnson, Marian S., Machida, Hiroko, Hasegawa, Kosei, Miyake, Takahito M., Nagano, Tadayoshi, Pejovic, Tanja, Shahzad, Mian MK, Im, Dwight D., Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., and Roman, Lynda D.

Published
2017
Full Text
View/download PDF

44. Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M. K., Im, Dwight D., Yoshida, Hiroshi, Enomoto, Takayuki, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

45. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma

Author

Matsuo, Koji, Takazawa, Yutaka, Ross, Malcolm S., Elishaev, Esther, Yunokawa, Mayu, Sheridan, Todd B., Bush, Stephen H., Klobocista, Merieme M., Blake, Erin A., Takano, Tadao, Baba, Tsukasa, Satoh, Shinya, Shida, Masako, Ikeda, Yuji, Adachi, Sosuke, Yokoyama, Takuhei, Takekuma, Munetaka, Yanai, Shiori, Takeuchi, Satoshi, Nishimura, Masato, Iwasaki, Keita, Johnson, Marian S., Yoshida, Masayuki, Hakam, Ardeshir, Machida, Hiroko, Mhawech-Fauceglia, Paulette, Ueda, Yutaka, Yoshino, Kiyoshi, Kajiwara, Hiroshi, Hasegawa, Kosei, Yasuda, Masanori, Miyake, Takahito M., Moriya, Takuya, Yuba, Yoshiaki, Morgan, Terry, Fukagawa, Tomoyuki, Pejovic, Tanja, Nagano, Tadayoshi, Sasaki, Takeshi, Richmond, Abby M., Post, Miriam D., Shahzad, Mian M. K., Im, Dwight D., Yoshida, Hiroshi, Enomoto, Takayuki, Omatsu, Kohei, Ueland, Frederick R., Kelley, Joseph L., Karabakhtsian, Rouzan G., and Roman, Lynda D.

Published
2018
Full Text
View/download PDF

47. TERT promoter hotspot mutations in breast cancer

Author

Shimoi, Tatsunori, Yoshida, Masayuki, Kitamura, Yuka, Yoshino, Tomomi, Kawachi, Asuka, Shimomura, Akihiko, Noguchi, Emi, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Kinoshita, Takayuki, Ichimura, Koichi, Fukuda, Takahiro, Fujiwara, Yasuhiro, and Tamura, Kenji

Published
2018
Full Text
View/download PDF

48. Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

Author

Sawada, Takeshi, Araki, Jungo, Yamashita, Toshinari, Masubuchi, Manami, Chiyoda, Tsuneko, Yunokawa, Mayu, Hoshi, Kumiko, Tao, Shoichi, Yamamura, Shohei, Yatsushiro, Shouki, Abe, Kaori, Kataoka, Masatoshi, Shimoyama, Tatsu, Maeda, Yoshiharu, Kuroi, Katsumasa, Tamura, Kenji, Sawazumi, Tsuneo, Minami, Hironobu, Suda, Yoshihiko, and Koizumi, Fumiaki

Published
2016
Full Text
View/download PDF

50. Risk-reducing decisions regarding germline BRCApathogenic variant: focusing on the timing of genetic testing and RRSO

Author

Abe, Akiko, Nomura, Hidetaka, Fusegi, Atsushi, Yunokawa, Mayu, Ueki, Arisa, Habano, Eri, Arakawa, Hiromi, Kaneko, Keika, Minoura, Yuko, Inari, Hitoshi, Ueno, Takayuki, and Kanao, Hiroyuki

Abstract

BackgroundIn Japan, the public insurance policy was revised in 2020 to cover hereditary breast and ovarian cancer (HBOC), including genetic testing and surveillance, for patients with breast cancer (BC). Consequently, the demand for risk-reducing salpingo-oophorectomy (RRSO) has increased. This study aimed to clarify the changes in the demand and timing of genetic testing and RRSO associated with public insurance coverage for HBOC in Japan.MethodsThis retrospective analysis included 350 women with germline BRCA(gBRCA) pathogenic variants (PVs) who had visited gynaecologists; they received gBRCAgenetic testing at 45.1±10.6 (20–74) years. The use of medical testing and preventive treatment was compared between the preinsurance and postinsurance groups using Mann-Whitney U and Fisher’s exact tests.ResultsThe findings indicate that RRSO rates doubled from 31.4% to 62.6% among patients with gBRCA-PV. The implementation rate was 32.4% among unaffected carriers and 70.3% among BC-affected patients. Younger patients received genetic testing with significantly shorter intervals between BC diagnosis and genetic testing and between genetic testing and RRSO.ConclusionOverall, the insurance coverage for HBOC patients with BC has increased the frequency of RRSO in Japan. However, a comparison between the number of probands and family members indicated that the diagnosis among family members is inadequate. The inequality in the use of genetic services by socioeconomic groups is an issue of further concern.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results